SLC16A1 and neoplasm: Overall, 47 (43.5%) breast cancer specimens exhibited high expression of both MCT1 and CD163Margin, and this combined high expression was significantly correlated with tumor size (p = 0.025), ER status (p = 0.038), PR status (p = 0.002), and increased Ki67 staining (p < 0.0001) (Table 1).